Last week’s Cardiovascular Research Technology conference heard George W. Vetrovec, M.D., of Virginia Commonwealth University Medical Center suggest that the robotic CorPath system from Corindus could potentially raise the standard of care for percutaneous coronary intervention (PCI). Corindus Vascular Robotics focuses on providing precision vascular robotic systems.
“The CorPath vascular robotic system can potentially foster a new standard of care for precise stent deployment – which is a big challenge today due to the limited precision associated with manually controlled PCI procedures,” said Dr. Vetrovec. “My personal experience using the CorPath system leads me to believe that the system potentially offers interventional cardiologists and their patients several significant procedural advantages over the current manual PCI procedure.”
“Our CorPath system is designed to significantly reduce radiation exposure, physician fatigue and other occupational hazards to physicians by allowing him or her to operate in an ergonomically correct position while being shielded from harmful and repeated radiation exposure. Our product offering comes at a time when the FDA has, just last month, unveiled its initiative to reduce unnecessary radiation exposure from medical imaging,” added David M. Handler, President and CEO of Corindus. “We are looking forward to the initiation of CorPath clinical trials.”
Percutaneous coronary intervention (PCI), commonly known as coronary angioplasty or simply angioplasty, is a procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is performed by an interventional cardiologist in a cath lab utilizing x-ray angiography imaging equipment.